Targeted antibody and cytokine cancer immunotherapies through collagen affinity

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945

Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review

Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400

The future of immune checkpoint therapy

Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229

To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery

Danhier, F., Féron, O., & Véronique Préat, A. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.08.027 · Cited by 2,891

Spatiotemporally programming cytokine immunotherapies through protein engineering

Santollani, L., & Wittrup, K. D. (2023) · Immunological Reviews · doi:10.1111/imr.13234 · Cited by 19

Targeting collagen in tumor extracellular matrix as a novel targeted strategy in cancer immunotherapy

Liu, J., Pan, D., Huang, X., Wang, S., Chen, H., Zhu, Y. Z., & Ye, L. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1225483 · Cited by 19

The integrated stress response promotes immune evasion through lipocalin 2

Bossowski, J. P., Pillai, R., Kilian, J., Lau, A. W., Nakamura, M., Rashidfarrokhi, A., Hao, Y., Li, R., Wu, K., Hattori, T., et al. (2026) · Nature · doi:10.1038/s41586-026-10143-0 · Cited by 19

CD8+ T cell priming that is required for curative intratumorally anchored anti-4-1BB immunotherapy is constrained by Tregs

Palmeri, J. R., Lax, B. M., Peters, J. M., Duhamel, L., Stinson, J. A., Santollani, L., Lutz, E. A., Pinney, W., Bryson, B. D., & Wittrup, K. D. (2024) · Nature Communications · doi:10.1038/s41467-024-45625-0 · Cited by 18

Collagen-binding IL-12-armoured STEAP1 CAR-T cells reduce toxicity and treat prostate cancer in mouse models

Sasaki, K., Bhatia, V., Asano, Y., Bakhtiari, J., Kaur, P., Wang, C., Matsuo, T., Dubois, O., Chiu, P.-C., Gun, D., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01508-3 · Cited by 18

The Versatility of Collagen in Pharmacology: Targeting Collagen, Targeting with Collagen

Revert‐Ros, F., Ventura, I., Prieto-Ruiz, J. Á., Hernández‐Andreu, J. M., & Revert, F. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126523 · Cited by 18

Reversibly photoswitchable protein assemblies with collagen affinity for in vivo photoacoustic imaging of tumors

Chen, S., Li, K., Chen, X., Shan, L., Lin, J., & Huang, P. (2024) · Science Advances · doi:10.1126/sciadv.adn8274 · Cited by 17

Cytotoxic IgG: Mechanisms, functions, and applications

Wöhner, M., & Nimmerjahn, F. (2025) · Immunity · doi:10.1016/j.immuni.2025.05.008 · Cited by 18

Facts and Hopes: Immunocytokines for Cancer Immunotherapy

Pabani, A., & Gainor, J. F. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1837 · Cited by 17

Transformable Gel‐to‐Nanovaccine Enhances Cancer Immunotherapy via Metronomic‐Like Immunomodulation and Collagen‐Mediated Paracortex Delivery

Jin, S. M., Cho, J. H., Gwak, Y., Park, S. H., Choi, K., Choi, J., Shin, H. S., Hong, J., Bae, Y., Ju, J., et al. (2024) · Advanced Materials · doi:10.1002/adma.202409914 · Cited by 16

Tumor-Localized Interleukin-2 and Interleukin-12 Combine with Radiation Therapy to Safely Potentiate Regression of Advanced Malignant Melanoma in Pet Dogs

Stinson, J. A., Barbosa, M. M. P., Sheen, A. M., Momin, N., Fink, E., Hampel, J., Selting, K. A., Kamerer, R. L., Bailey, K. L., Wittrup, K. D., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0861 · Cited by 17

Is Immunotherapy the Holy Grail for Pancreatic Cancer?

Andersson, R. E., Pereira, C., Bauden, M. P., & Ansari, D. (2019) · Immunotherapy · doi:10.2217/imt-2019-0164 · Cited by 14

CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity

Mehta, N. K., Rakhra, K., Meetze, K. A., Li, B., Momin, N., Chang, J. Y. H., Wittrup, K. D., Baeuerle, P. A., & Michaelson, J. S. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0636 · Cited by 16

Biomaterials for protein delivery for complex tissue healing responses

Dorogin, J., Townsend, J. M., & Hettiaratchi, M. H. (2021) · Biomaterials Science · doi:10.1039/d0bm01804j · Cited by 15

Decoding the body language of immunity: Tackling the immune system at the organism level

Chevrier, N. (2019) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2019.10.010 · Cited by 13

Engineering enhanced chimeric antigen receptor-T cell therapy for solid tumors

Neeser, A., Ramasubramanian, R., Wang, C., & Ma, L. (2023) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2023.100385 · Cited by 13

Impact of drug dispersion on tumor-effector dynamics during combined chemo-immunotherapy with sensitivity analysis

Mashiku, L. R., Ndenda, J. P., Maghembe, R. S., & Shaw, S. (2024) · Applied Mathematical Modelling · doi:10.1016/j.apm.2024.06.002 · Cited by 12

Probiotic-mediated tumor microenvironment reprogramming with protease-sensitive interleukin-15 and photothermal therapy

Wang, H., Zheng, L., Yang, C., Lin, J. H., Zhou, R., Liu, H., Dong, Y., Xu, X., Shi, G., Yang, J., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102191 · Cited by 12

Advances in engineering and delivery strategies for cytokine immunotherapy

Bohmer, M., Xue, Y., Jankovic, K. E., & Dong, Y. (2023) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2208344 · Cited by 11

An engineered immunocytokine with collagen affinity improves the tumor bioavailability, tolerability, and therapeutic efficacy of IL-2

Silver, A. B., Tzeng, S. Y., Lager, M., Wang, J., Ishihara, J., Green, J. J., & Spangler, J. B. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101289 · Cited by 11

Noncovalently particle-anchored cytokines with prolonged tumor retention safely elicit potent antitumor immunity

Niu, L., Jang, E., Chin, A. L., Huo, Z., Wang, W., Cai, W., & Tong, R. (2024) · Science Advances · doi:10.1126/sciadv.adk7695 · Cited by 11

Nanoparticle approaches for manipulating cytokine delivery and neutralization

Wang, R., Kubiatowicz, L. J., Zhang, R., Bao, L., Fang, R. H., & Zhang, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1592795 · Cited by 13

Emerging innovations in nanomedicine for cancer immunotherapy

Shah, J. R., Kapoor, D. U., & Prajapati, B. G. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.106584 · Cited by 11

Development of Cancer Immunotherapies

DeLucia, D. C., & Lee, J. K. (2022) · Cancer treatment and research · doi:10.1007/978-3-030-96376-7_1 · Cited by 10

Balancing safety and efficacy: tuning the biodistribution and pharmacokinetics of cytokine immunotherapies

Momin, N. (2023) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2023.102994 · Cited by 9

A versatile platform for the tumor-targeted delivery of immune checkpoint-blocking immunoglobin G

Fan, J., Feng, Y., Tao, Z., Chen, J., Yang, H., Shi, Q., Zhao, L., She, T., Li, H., Jin, Y., et al. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.11.003 · Cited by 9

Prospect of bacteria for tumor diagnosis and treatment

Xu, Y., Zhao, C., Ma, X., & Zhang, H. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121215 · Cited by 9

The hypoxic ECM and neutrophils in MIBC immunotherapy resistance

Child, F., Lunj, S., Gough, J. E., Humphries, M. J., Biolatti, L. V., Hoskin, P., Choudhury, A., & Quiles, C. G. (2025) · Nature Reviews Urology · doi:10.1038/s41585-025-01092-w · Cited by 8

Targeted drug delivery system for ovarian cancer microenvironment: Improving the effects of immunotherapy

Peng, H., He, X., & Wang, Q. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1035997 · Cited by 9

The Crucial Nexus: Unveiling the Role of Collagen in Cancer Progression

Reeva, H., Mahesh, G., Manjunath, U., Selvamurugan, N., & Mohankumar, D. (2025) · Seminars in Oncology · doi:10.1016/j.seminoncol.2025.152346 · Cited by 7

Collagen Anchoring Protein-Nucleic Acid Chimeric Probe for In Situ In Vivo Mapping of a Tumor-Specific Protease

Xie, X., Sun, Y., Peng, J., Zhang, Z., Wang, M., Wang, Z., Lei, C., Huang, Y., & Nie, Z. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.3c03775 · Cited by 7

Engineering Anticytokine Antibodies for Immune Modulation

Tomala, J., Cao, S. D., & Spangler, J. B. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2300467 · Cited by 7

Targeting collagen in “armored and cold” tumors: Overcoming barriers to cancer therapy

Wang, S., Li, J., & Zhao, Y. (2024) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2024.11.001 · Cited by 6

Around the collagen triple helix: an introduction to studying associated genetic and acquired diseases

Boudko, S. P. (2025) · Matrix Biology · doi:10.1016/j.matbio.2025.07.003 · Cited by 6

Optical Control of Cytokine Signaling via Bioinspired, Polymer-Induced Latency

Perdue, L. A., Do, P., David, C., Chyong, A., Kellner, A. V., Ruggieri, A. N., Kim, H. R., Salaita, K. S., Lesinski, G. B., Porter, C. C., et al. (2020) · Biomacromolecules · doi:10.1021/acs.biomac.0c00264 · Cited by 6

A collagen-immobilized nanodevice for in situ ratiometric imaging of cancer biomarkers in the tumor microenvironment

Tian, F., Zhou, S., Xie, S., Zhang, Z., Peng, L., Jiang, L., Wang, Z., Nie, Z., & Huang, Y. (2023) · Chemical Science · doi:10.1039/d3sc03972b · Cited by 7

Advances in interleukin-10-based therapies for pulmonary diseases: focus on targeted lung delivery systems

Tian, W., Wang, X., Zeng, J., Gao, Y., Tang, S., Ma, C., Ye, L., & Tian, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1630990 · Cited by 6

Engineering IL-10 and rapamycin to bind collagen leads to improved anti fibrotic efficacy in lung and kidney fibrosis

White, M. J. V., Raczy, M. M., Budina, E., Yuba, E., Solanki, A., Shim, H.-N., Zhang, Z. J., Gray, L. T., Cao, S., Alpar, A. T., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-94073-3 · Cited by 5

Tumor extracellular matrix enhances invasive gene expression of breast cancer cells in 3D patient-derived scaffolds

Pezeshki, P. S., Ganjaroudi, N. M., Azimzadeh, A., Zolbin, M. M., Mohammadpour, H., Miri, S. R., Molaei, H., & Kajbafzadeh, A. M. (2025) · Scientific Reports · doi:10.1038/s41598-025-12196-z · Cited by 4

Recent Developments in the Study of the Microenvironment of Cancer and Drug Delivery

Chaudhary, B., Kumar, P., Arya, P., Singla, D., Kumar, V., Kumar, D., Roshan, S., Wadhwa, S., Gulati, M., Singh, S. K., et al. (2022) · Current Drug Metabolism · doi:10.2174/1389200224666230110145513 · Cited by 4

Sheltering proteins from protease-mediated degradation and a de novo strategy for preventing acute liver injury

Shi, P., Tang, B., Zhou, S., Qin, J., Zan, X., & Geng, W. (2021) · Biomaterials Science · doi:10.1039/d1bm00063b · Cited by 4

Comprehensive characterization of immune landscape of Indian and Western triple negative breast cancers

Korlimarla, A., Hari, P. S., Prabhu, J. S., Ragulan, C., Patil, Y., Snijesh, V. P., Desai, K., Mathews, A., Appachu, S., Diwakar, R. B., et al. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101511 · Cited by 4

A collagen-binding SIRPαFc fusion protein for targeted cancer immunotherapy

Liu, J., Xu, T., Pan, D., Fan, J., Fu, Y., Huang, X., Zhao, W., Dong, X., Zhang, S., Kuerban, K., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110951 · Cited by 4

Collagen-Peptide-Based Drug Delivery Strategies

Jayaraman, A., Price, C., Sullivan, M. O., & Kiick, K. L. (2020) · Technology & Innovation · doi:10.21300/21.4.2020.9 · Cited by 3

Monitoring and modulation of the tumor microenvironment for enhanced cancer modeling

Head, T., & Cady, N. C. (2022) · Experimental Biology and Medicine · doi:10.1177/15353702221074293 · Cited by 3

Functional nucleic acid-based fluorescence imaging for tumor microenvironment monitoring: A review

Liang, Z., & Tian, F. (2025) · Analytica Chimica Acta · doi:10.1016/j.aca.2025.343794 · Cited by 4

Activity-attenuated serum albumin-fused interleukin-33 suppresses experimental autoimmune encephalomyelitis

Budina, E., Reda, J. W., Cao, S., Watkins, E. A., Solanki, A., Nguyen, M., Ang, P. S., Medellin, J. E. G., Chun, H.-R., Foley, C., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102231 · Cited by 3

Modification of nitric oxide donors onto a monoclonal antibody boosts accumulation in solid tumors

Yoshikawa, T., Phan, K. Q., Tagawa, H., Sasaki, K., Feng, H., Kishimura, A., Mori, T., & Katayama, Y. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119352 · Cited by 3

Nanomedicine – Immune System Interactions: Limitations and Opportunities for the Treatment of Cancer

Elsafy, S., Metselaar, J. M., & Lammers, T. (2023) · Handbook of experimental pharmacology · doi:10.1007/164_2023_685 · Cited by 3

Dynamic monitoring of the fibrosis disease by a collagen targeting near infrared probe

Zhang, X., Yang, Q., Zhou, S., Li, C., & Jiang, X. (2024) · Biomaterials Science · doi:10.1039/d3bm01926h · Cited by 3

Identification of Pancreatic Ductal Adenocarcinoma Extracellular Matrix Signatures from In-Depth Proteomic Profiling that Correlate with Lymphocyte Infiltration

Considine, J. M., Pally, D., O’Brien, S. A., Egan, J. N., Feng, D., Pignatelli, J., Kashyap, A. S., Sharma, N., & Naba, A. (2026) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0460 · Cited by 3

Therapeutic Intervention of Signaling Pathways in Colorectal Cancer

Chandra, V., Tiwari, A., Singh, R. P., & Desai, K. V. (2022) · Springer eBooks · doi:10.1007/978-3-030-72702-4_8 · Cited by 2

Supramolecular immunotherapy on diversiform immune cells

Wang, J., Zhang, Z., & Chen, Y. (2023) · Journal of Materials Chemistry B · doi:10.1039/d3tb00924f · Cited by 2

A novel method to produce synthetic murine CXCL10 for efficient screening of functional variants

Decalf, J., Tom, J., Mai, E., Hernández-Barry, H., Noland, C. L., Vollmar, B. S., Li, A., Li, H., Xie, D., Zhu, L., et al. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105376 · Cited by 1

Tregs constrain CD8 + T cell priming required for curative intratumorally anchored anti-4-1BB immunotherapyPreprint

Palmeri, J. R., Lax, B. M., Peters, J. M., Duhamel, L., Stinson, J. A., Santollani, L., Lutz, E. A., Pinney, W., Bryson, B. D., & Wittrup, K. D. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.30.526116 · Cited by 2

In-depth proteomic profiling of the extracellular matrix of pancreatic ductal adenocarcinomas identifies signatures correlating with lymphocyte infiltrationPreprint

Considine, J. M., Pally, D., O’Brien, S. A., Potts, J., Feng, D., Pignatelli, J., Kashyap, A. S., Sharma, N., & Naba, A. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.22.669728 · Cited by 2

Advancing precision tumor therapy: Progress in targeted delivery of peptide-based nanomaterials from microenvironment to organelles

Tian, K., Sheng, J., Chen, J., Zhang, M., Song, J., Wu, M., Zhao, Y., & Zhang, S. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.102820 · Cited by 1

Hemostasis at the edge between physiology and cancer

Galardi, A., Dell’Orto, E., Bianchi, F., Cosentino, G., Fogazzi, V., Pupa, S. M., & Iorio, M. V. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04294-1 · Cited by 1

Targeting tumor-specific T cells with LAG3-directed interleukin-2 prevents T-cell exhaustion and reinvigorates antitumor immunity

Yu, X., Liao, H., Lv, J., Sun, Y., Zhang, R., Chen, Y., Lin, Y., Liu, L., Li, S., Tang, H., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02667-8 · Cited by 2

Immunotherapy in Cancer: Biology Therapy

Khichade, M. D., Shafi, D. S., Nilangekar, P. S., Gandhle, A. S., Gurav Mohini, A., & Phulsundar, V. B. (2022) · Journal of Biomedical and Pharmaceutical Research · doi:10.32553/jbpr.v11i5.937 · Cited by 1

Improving safety and efficacy of immunotherapeutics

Crunkhorn, S. (2019) · Nature Reviews Drug Discovery · doi:10.1038/d41573-019-00081-0 · Cited by 1

Molecular and Macroscopic Therapeutic Systems for Cytokine‐Based Cancer Immunotherapy

Jin, S. M., Lee, S. N., Yoo, Y. J., & Lim, Y. T. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100026 · Cited by 1

Overcoming transport barriers to immunotherapy

Yu, S. S., Hubbell, J. A., & Swartz, M. A. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-01084-4 · Cited by 2

Role of Immunotherapy in Ameliorating Proteopathic Dementia

Singh, M., Pancham, P., Agarwal, S., Kaur, H., Agarwal, V., Tiwari, R. K., Mani, S., & Rachana, R. (2022) · Springer eBooks · doi:10.1007/978-981-16-7606-2_16 · Cited by 1

Engineered collagen-targeting therapeutics reverse lung and kidney fibrosis in micePreprint

White, M. J. V., Raczy, M. M., Budina, E., Yuba, E., Solanki, A., Shim, H.-N., Zhang, Z. J., Gray, L. T., Cao, S., Alpar, A. T., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.04.474747 · Cited by 1

Immunotherapy of solid tumors: multimodal imaging strategies for chimeric antigen receptor T cell tracking in the tumor microenvironment

Henze, J. (2021) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-8758 · Cited by 1

Studying von Willebrand factor from bioengineering point of view

Ishihara, J. (2020) · Japanese Journal of Thrombosis and Hemostasis · doi:10.2491/jjsth.31.345

Protagonist of Immuno-Profiling, Immuno-Scoring, and Immunotherapy Towards Colitis-Associated Cancer

Adil, A. M., Vaithy.k, A. K., Pandurangan, A. K., Waseem, M., & Ahmed, N. (2021) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-7998-3580-6.ch002

A comprehensive analysis of immune landscape of Indian triple negative breast cancerPreprint

Korlimarla, A., Hari, P., Prabhu, J. S., Ragulan, C., Patil, Y., Snijesh, V. P., Desai, K., Mathews, A., Appachu, S., Diwakar, R. B., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.06.483159

Tuneable 3D biocompatible scaffolds for biological and biophysical solid-tumour microenvironment studies; applications in Ovarian Cancer

Paradiso, F. (2022) · Cronfa (Swansea University) · doi:10.23889/suthesis.60122

Engineered Collagen-Targeting Therapeutics Treat Lung and Kidney Fibrosis in MicePreprint

White, M. J. V., Raczy, M. M., Budina, E., Yuba, E., Solanki, A., Shim, H.-N., Zhang, Z. J., Gray, L. T., Cao, S., Alpar, A. T., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4163649

Potential of Biotechnology in Cancer Management

George, A., Varghese, J., & Padinharayil, H. (2023) · Springer eBooks · doi:10.1007/978-981-99-5281-6_2

1213 Tumor-ECM targeted IL-12: improved safety and efficacy in clinically relevant settings

Ishihara, J. (2023) · Regular and Young Investigator Award Abstracts · doi:10.1136/jitc-2023-sitc2023.1213

Tailoring the bioactivities of IL-12 for cancer immunotherapy with mRNA-based technology: from immunocytokines to armored T cell transfer

Di-Trani, C. A. (. A. (2023) · Deposito Adademico Digital Universidad De Navarra (University of Navarra) · doi:10.15581/10171/67876

Nanotechnology-enhanced immunotherapy for cancer

Naik, A. R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13209-4.00001-5

Cytokines released by human tumors are independent from cancer histotype

Kuksin, M., Mouraud, S., Bredel, D., Radulescu, C., Mohamed-Djalim, C., Adam, J., Terrier, P., de Montpréville, V., Zitvogel, L., Scoazec, J., et al. (2026) · European Journal of Cancer · doi:10.1016/j.ejca.2026.116864

CD74 regulates antitumor immunity in melanoma by reprogramming dendritic cell immunogenicity and migrationPreprint

Maranou, E., Park, G., Weinzettl, P., Alanko, J., Pulkkinen, O. I., Coupland, S. E., Salmi, M., & Figueiredo, C. R. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.01.691518

Upregulated CCN1 from pleural mesothelial cells alters collagen I conformation and drives fibrosis via ITGB1/MAPK signaling

Cui, X.-L., Song, L.-J., Li, Q., Jia, Z.-H., Dai, X., Wang, M., Lv, Y., Chen, S.-J., Zhang, H.-D., Cheng, P.-P., et al. (2026) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-026-00928-6

Covalent tumor anchoring spatially orchestrates antitumor immunityPreprint

Li, Q., Chen, H., Zhang, P., Cao, L., Yu, B., & Wang, L. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.13.724746

Marker‐Agnostic Tumor Anchoring Chimeras Enable pH‐Gated Immune Engagement

Lauwers, H., Baere, J. D., Aernout, I., Cappellesso, F., Munter, S. D., Defreyne, D., Neeser, A., Grzywa, T. M., Bosteels, V., Vandekerckhove, B., et al. (2026) · Angewandte Chemie International Edition · doi:10.1002/anie.202525715

Marker‐Agnostic Tumor Anchoring Chimeras Enable pH‐Gated Immune Engagement

Lauwers, H., Baere, J. D., Aernout, I., Cappellesso, F., Munter, S. D., Defreyne, D., Neeser, A., Grzywa, T. M., Bosteels, V., Vandekerckhove, B., et al. (2026) · Angewandte Chemie · doi:10.1002/ange.202525715

Cytokine delivery and targeting strategies in pet dogs with cancer: a comparative immuno-oncology approach

Barbosa, M. M. P., & Fan, T. M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1906933

Beyond Structure: The Dynamic Role of the Extracellular Matrix Components in Immune Evasion

Maqbool, M., Surendranath, A., Baba, S. K., Jawwad, T., Elfaki, I., Mir, R., Kumar, R., Shahab Uddin, M. S., Haris, M., Macha, M. A., et al. (2026) · 癌症：英文版 · doi:10.34133/cancomm.0045

Intradermal immunoengineering with mRNA

Patino, T. M., & Peeler, D. J. (2026) · Nanomedicine · doi:10.1080/17435889.2026.2715088

Collagen‐Binding IL‐15 Immunocytokine Armed Oncolytic Adenovirus Establishes a Self‐Reinforcing Immunostimulatory Milieu to Potentiate Antitumor Immunity

Yang, Y., Liu, X., Ding, J., Xu, J., Zhang, J., Zhang, H., Zhang, W., Li, S., Lü, Z., Su, R., et al. (2026) · Advanced Science · doi:10.1002/advs.77691

Understanding and targeting the tumour matrisome

Pally, D., Englund, J. I., & Naba, A. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01203-5

Preclinical–Clinical Discrepancies in Immune Checkpoint Inhibitor Efficacy for Triple-Negative Breast Cancer: Disease Stage, Antibody Properties, Biomarker Alignment, and Model Limitations

Zhang, Y., Paing, H., & Wang, J. (2026) · Cancers · doi:10.3390/cancers18193099

Collagen targeting IL-12 combined with Doxorubicin enhances the anti-tumor effect against osteosarcoma

Matsuo, T., Noblecourt, L., Kaur, P., Wang, C., Chiu, P.-C., Sasaki, K., Hosokawa, T., Singh, C., Lärkeryd, A., Ueno, T., et al. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115414

Computational Design and Structure-Guided Optimization of Anti-Osteopontin Monoclonal Antibodies at the Intersection of Obesity, Type 2 Diabetes, and Hepatocellular Carcinoma

Shams, E., Rismani, E., Sarabi, P. A., Nasiri‐Toosi, M., Malekzadeh, R., Hassan, M., & Vosough, M. (2026) · Journal of Genome Biotechnology and Genetics · doi:10.3390/jgbg1030019

Reprogramming the tumor microenvironment from within: intratumoral immunoadjuvants in cancer immunotherapy

Tong, A. P. S., Poljakov, K., Lane, D. D., Laidlaw, G., Monsky, W. L., McGregor, H., Yeung, R. S., Grassberger, C., Altreuter, D. H., Hall, E. T., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2026-015165

Collagen affinity improves efficacy and safety of antibody and cytokine cancer immunotherapy.

Ishihara, A., Ishihara, J., Hubbell, J. A., & Swartz, M. A. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.e14232

Abstract IA07: Using matrix protein affinity to modulate the tumor microenvironment

Ishihara, J., Ishihara, A., Saskai, K., Lee, S. S.-Y., Yasui, M., Abé, H., Potin, L., Hosseinchi, P., Fukunaga, K., Raczy, M. M., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6074.cricimteatiaacr18-ia07

Abstract 1553: Collagen affinity improves safety and efficacy of antibody and cytokine cancer immunotherapies

Ishihara, J., Ishihara, A., Mansurov, A., Sasaki, K., Lee, S. S., Williford, J., Potin, L., Hosseinchi, P., Gray, L. T., Katsumata, K., et al. (2019) · Immunology · doi:10.1158/1538-7445.sabcs18-1553

Improving safety and efficacy of immunotherapeutics

Crunkhorn, S. (2019) · Nature Reviews Drug Discovery · doi:10.1038/d41573-019-00081-0 · Cited by 1

A collagen-binding SIRPαFc fusion protein for targeted cancer immunotherapy

Liu, J., Xu, T., Pan, D., Fan, J., Fu, Y., Huang, X., Zhao, W., Dong, X., Zhang, S., Kuerban, K., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110951 · Cited by 4